1.HIV and paraquat poisoning: fighting fire with fire?
Journal of Zhejiang University. Science. B 2018;19(2):168-170
Though the cases of HIV patients with paraquat (PQ) poisoning are rare, we still found the common features. These recovered HIV patients tended to result in much less lung injury, and had low CD4+ T lymphocyte levels due to HIV infection, which meant they were under the immunosuppressive condition during treatment. This may be conducive to relieve the acute inflammation and lung fibrosis induced by PQ. Thus, we consider the immunosuppressive therapy for PQ poisoning to be appropriate. However, the drugs used currently may be not optimal for toxic patient. As next step, we will add the CD4+ T lymphocyte-targeted immunosuppressive drug to treat PQ poisoning patients.
CD4-Positive T-Lymphocytes/immunology*
;
HIV Infections/immunology*
;
Humans
;
Immunosuppressive Agents/therapeutic use*
;
Paraquat/poisoning*
2.Chronic Cyclosporine Nephrotoxicity: New Insights and Preventive Strategies.
Can LI ; Sun Woo LIM ; Bo Kyung SUN ; Chul Woo YANG
Yonsei Medical Journal 2004;45(6):1004-1016
Cyclosporine (CsA) has improved patient and graft survival rates following solid-organ transplantation and has been increasingly applied with significant clinical benefits in the management of autoimmune diseases. However, the clinical use of CsA is often limited by acute and chronic nephrotoxicity, which remains a major problem. Acute nephrotoxicity depends on the dosage of CsA and seems to be caused by a reduction in renal blood flow related to afferent arteriolar vasoconstriction. However, the mechanisms underlying chronic CsA nephrotoxicity are not fully understood. Activation of the intrarenal renin-angiotensin system, increased release of endothelin-1, dysregulation of nitric oxide (NO) and NO synthase, upregulation of transforming growth factor-beta1, inappropriate apoptosis, stimulation of inflammatory mediators, and enhanced immunogenecity have all been implicated in the pathogenesis of chronic CsA nephrotoxicity. Reducing the CsA dose or withdrawing it and using combined nephroprotective drugs (mycophenolate mofetil, losartan, and pravastatin) may ameliorate chronic CsA-induced renal injury. This review discusses new insights and preventive strategies for this clinical dilemma.
Animals
;
Chronic Disease
;
Cyclosporine/*poisoning/therapeutic use
;
Humans
;
Immunosuppressive Agents/*poisoning/therapeutic use
;
Kidney Diseases/*chemically induced/*prevention & control
;
*Organ Transplantation
;
Research Support, Non-U.S. Gov't